FDA approves Afrezza to treat diabetes

 The U.S. Food and Drug Administration has approved Afrezza (insulin human) Inhalation Powder.

A rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus.
Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal.

Original source.

Registration

Register for receiving PharmaAround news, register for PharmAround events.
Continue registration